Gene · 259197
Papers4,252
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 4,252
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multiple Myeloma Cells Shift the Fate of Cytolytic ILC2s Towards TIGIT-Mediated Cell Death. | Cancers (Basel) | 2025 | 39858045 | PubTator, text mining | PubMed |
| Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30. | Mol Ther Oncol | 2025 | 39811682 | PubTator, text mining | PubMed |
| Uncovering NK cell sabotage in gut diseases via single cell transcriptomics. | PLoS One | 2025 | 39752457 | PubTator, text mining | PubMed |
| Recognition of Self and Viral Ligands by NK Cell Receptors. | Immunol Rev | 2025 | 39748148 | PubTator, text mining | PubMed |
| Genetic analysis uncovers potential mechanisms linking juvenile ldiopathic arthritisto breast cancer: A Bioinformatic Pilot study. | Cancer Genet | 2025 | 39729926 | PubTator, text mining | PubMed |
| NK-cell cytotoxicity toward pluripotent stem cells and their neural progeny: impacts of activating and inhibitory receptors and KIR/HLA mismatch. | Stem Cells | 2025 | 39708357 | PubTator, text mining | PubMed |
| Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy. | Cytotherapy | 2025 | 39570247 | PubTator, text mining | PubMed |
| Intra- and Extrahepatic Cholangiocarcinomas Display Differing Sensitivities to NK Cell Lysis and Modulate NK Cell Function through Shared and Distinct Pathways. | Mol Cancer Res | 2025 | 39436670 | PubTator, text mining | PubMed |
| Expression of CD226 on γδ T cells is lower in advanced chronic lymphocytic leukemia and correlates with IgA, IgG and LDH levels. | Adv Clin Exp Med | 2025 | 38819939 | PubTator, text mining | PubMed |
| Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. | medRxiv | 2025 | 38014192 | PubTator, text mining | PubMed |
| Prognostic impact of MALs and potential immunotherapy targets in uveal melanoma. | Pediatr Discov | 2024 | 40625454 | PubTator, text mining | PubMed |
| Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy. | Autophagy Rep | 2024 | 40395527 | PubTator, text mining | PubMed |
| Natural killer cell engagers for cancer immunotherapy. | Front Oncol | 2024 | 39911822 | PubTator, text mining | PubMed |
| Characterization of the Bone Marrow Lymphoid Microenvironment and Discovery of Prognostic Immune-Related Factors in Acute Myeloid Leukemia. | Int J Mol Sci | 2024 | 39684749 | PubTator, text mining | PubMed |
| Statistical methods for comparing two independent exponential-gamma means with application to single cell protein data. | PLoS One | 2024 | 39671382 | PubTator, text mining | PubMed |
| Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma. | Anticancer Res | 2024 | 39626933 | PubTator, text mining | PubMed |
| Analysis of the Blood Levels of NK and NKT Cells in Patients with Severe SARS-CoV-2 Infection. | Iran J Immunol | 2024 | 39624905 | PubTator, text mining | PubMed |
| Exercise: a non-drug strategy of NK cell activation. | Braz J Med Biol Res | 2024 | 39607207 | PubTator, text mining | PubMed |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | 39579618 | PubTator, text mining | PubMed |
| Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity. | Sci Rep | 2024 | 39506082 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/259197/papers?page=8